Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Placebo Controlled, Double Blind Phase 1b/2 Study of U3-1287 (AMG 888) in Combination With Trastuzumab Plus Paclitaxel in Newly Diagnosed HER2 Positive Metastatic Breast Cancer (MBC)

NCT01512199 is registered in ClinicalTrials.gov with Daiichi Sankyo as lead sponsor.

NCT NCT01512199
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01512199 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Placebo Controlled, Double Blind Phase 1b/2 Study of U3-1287 (AMG 888) in Combination With Trastuzumab Plus Paclitaxel in Newly Diagnosed HER2 Positive Metastatic Breast Cancer (MBC)
Lead sponsor
Daiichi Sankyo
Phase
Phase 1/2
Overall status
Terminated
Start date
November 30, 2011
Completion date
January 28, 2015
Enrollment
29 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic breast cancer